Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice

PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AEs), and impact of dos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Roeker, Lindsey E., Fox, Christopher P., Eyre, Toby A., Brander, Danielle M., Allan, John N., Schuster, Stephen J., Nabhan, Chadi, Hill, Brian T., Shah, Nirav N., Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce D., Lamanna, Nicole, Singavi, Arun K., Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Tuncer, Hande H., Winter, Allison M., Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John M., Williams, Annalynn M., Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy A., Mato, Anthony R.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020996/
https://ncbi.nlm.nih.gov/pubmed/31004001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0361
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars